DarioHealth Corp. announced that Research2Guidance, an analyst and strategic consulting company for the digital health industry, published an interview of DarioHealth CEO, Erez Raphael titled “Using real-time data to feed predictive care models for diabetes management.”
CAESAREA, Israel, July 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Research2Guidance, an analyst and strategic consulting company for the digital health industry, published an interview of DarioHealth CEO, Erez Raphael titled “Using real-time data to feed predictive care models for diabetes management.” The interview covers topics including DarioHealth’s position and strategy in the digital health market, as well as industry trends and a look at how users integrate digital health technologies into their daily lives to create measurable health benefits. To read the article in full, please visit: https://research2guidance.com/using-real-time-data-to-feed-predictive-care-models-for-diabetes-management-interview-with-erez-raphael-ceo-at-dariohealth/
http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, we are using forward-looking statements in the Research2Guidance interview, when we discuss the benefits of our products to users, how our capabilities help us empower diabetes patients and make a significant difference in their lives, when we discuss that more engaged users will lead to improvements in clinical outcomes, when we discuss that we are looking into successfully expanding our international market presence and having the same pricing model helps us reach our revenue and profitability goals, when we discuss acceleration of our penetration, when we discuss penetration rates of digital health solutions, or that when digital health diabetes solutions reach market penetration of 5%-10%, DarioHealth will be one of the leading players digitizing diabetes management, when we discuss expanding our business in the future to serve and help improve the lives of patients with other chronic conditions, or when we discuss our plan to accelerate user growth and to be a dominant player in the market, and that this should result in significantly higher revenue for the company.
Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter,
VP Marketing,
joao@mydario.com
1-914-775-5548
DarioHealth Investor Relations Contact:
Westwicke Partners
Dario@Westwicke.com
1-443-213-0500
View original content:http://www.prnewswire.com/news-releases/dariohealth-ceo-erez-raphaels-interview-published-in-research-2-guidance-300680056.html
SOURCE DarioHealth Corp.
